Health Impact Projection of Introducing the Anti-PD-(L)1 Class across 10 Cancers Indications in Japan
Author(s)
Aguiar-Ibáñez R1, Hughes R2, Perera C2, Taniguchi K3, Ohno T3, Abe M3, Franceschini M2, Heron L2
1Merck Canada Inc, Toronto, ON, Canada, 2Adelphi Values PROVE, Bollington, UK, 3MSD K.K., Tokyo, Japan
Presentation Documents
OBJECTIVES: To estimate the impact in health outcomes that anti-PD(L)1 inhibitors had in Japan among patients with cancer who initiated treatment between 2017-2021, including: adjuvant and metastatic melanoma, and metastatic NSCLC, urothelial, head and neck, renal cell carcinoma, gastric, oesophageal and colorectal cancers. Two scenarios were compared: one without anti-PD-(L)1 targeted treatments (where patients were treated with standard of care [SOC]), and one where patients could be treated with anti-PD-(L)1s. METHODS: A Health Impact Projection (HIP) model was developed that retrospectively estimated life years (LYs), progression-free survival (PFS) and quality-adjusted life years (QALYs) across the indications the included following the market approval of PD-(L)1 inhibitors in Japan. A partitioned survival model was used to estimate key survival outcomes. Survival and adverse event data were based on pivotal clinical trials in the corresponding indications. The incidence of each cancer type was based on data from the Japanese National Cancer Registry database. Other Japanese-specific data sources were used to derive other epidemiology inputs (e.g. stage at diagnosis, recurrence rates, treatment rates per line, etc.) and the market uptake to reflect the proportion of patients receiving an anti-PD-(L)1 rather than SOC.
RESULTS:
The model estimated that 182,432 patients initiated treatment with anti‐PD‐(L)1 therapies across the included indications between 2017-2021. The use of anti-PD(L)1s resulted in gains of 116,407 LYs (relative gain: +18%), 94,377 PFS years (+35%), and 103,852 QALYs (+11%) compared to a hypothetical scenario without anti-PD-(L)1 treatments available. Anti‐PD‐(L)1 usage in NSCLC, followed by urothelial carcinoma, contributed the most to the estimated total LYs gained.CONCLUSIONS:
Following the approval of anti-PD‐(L)1 inhibitors, patients with cancer initiating treatment with anti-PD(L)1 inhibitors between 2017-2021 across the included indications experienced significant gains in life expectancy, PFS and quality of life, demonstrating the benefit brought by anti-PD‐(L)1 inhibitors to patients with cancer in Japan.Conference/Value in Health Info
2023-05, ISPOR 2023, Boston, MA, USA
Value in Health, Volume 26, Issue 6, S2 (June 2023)
Code
EE398
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
No Additional Disease & Conditions/Specialized Treatment Areas